It’s been an eventful few quarters for Boehringer Ingelheim GmbH in India and the German multinational appears to be taking the general turbulence in its stride, dealing deftly with infringement activity and building momentum for star brands such as Jardiance (empagliflozin), recently approved in the country for heart failure across the full spectrum of ejection fraction.
Boehringer has over the recent past stopped a handful of Indian companies in their tracks, at least for now, on charges of infringing its local
It recently secured ad interim injunctions against the domestic firms MacLeods, Eris, MSN Labs, Emcure Pharmaceuticals and Optimus Pharma that launched cut-price